The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients with induced immune responses and a prolonged OS.
Yoshihiro Yoshitake
No relevant relationships to disclose
Daiki Fukuma
No relevant relationships to disclose
Akira Yuno
No relevant relationships to disclose
Masatoshi Hirayama
No relevant relationships to disclose
Hideki Nakayama
No relevant relationships to disclose
Takuya Tanaka
No relevant relationships to disclose
Masashi Nagata
No relevant relationships to disclose
Kenta Kawahara
No relevant relationships to disclose
Yoshihiro Nakagawa
No relevant relationships to disclose
Ryoji Yoshida
No relevant relationships to disclose
Hidenao Ogi
No relevant relationships to disclose
Akimitsu Hiraki
No relevant relationships to disclose
Hirofumi Jono
No relevant relationships to disclose
Akinobu Hamada
No relevant relationships to disclose
Koji Yoshida
Employment or Leadership Position - OncoTherapy Science
Takuya Tsunoda
Employment or Leadership Position - OncoTherapy Science
Yasuharu Nishimura
No relevant relationships to disclose
Yusuke Nakamura
Consultant or Advisory Role - OncoTherapy Science (U)
Stock Ownership - OncoTherapy Science
Masanori Shinohara
No relevant relationships to disclose